ES2270047T3 - Proceso para preparar inhibidores de la fosfodiesterasa v de xantina y sus precursores. - Google Patents
Proceso para preparar inhibidores de la fosfodiesterasa v de xantina y sus precursores. Download PDFInfo
- Publication number
- ES2270047T3 ES2270047T3 ES03734281T ES03734281T ES2270047T3 ES 2270047 T3 ES2270047 T3 ES 2270047T3 ES 03734281 T ES03734281 T ES 03734281T ES 03734281 T ES03734281 T ES 03734281T ES 2270047 T3 ES2270047 T3 ES 2270047T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- baselineskip
- alkyl
- group
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38447802P | 2002-05-31 | 2002-05-31 | |
US384478P | 2002-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2270047T3 true ES2270047T3 (es) | 2007-04-01 |
Family
ID=29712039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES03734281T Expired - Lifetime ES2270047T3 (es) | 2002-05-31 | 2003-05-30 | Proceso para preparar inhibidores de la fosfodiesterasa v de xantina y sus precursores. |
Country Status (17)
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
NZ528216A (en) * | 2001-02-24 | 2006-12-22 | Boehringer Ingelheim Pharma | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
TW200404802A (en) * | 2002-05-31 | 2004-04-01 | Schering Corp | Xanthine phosphodiesterase V inhibitor polymorphs |
WO2004009091A1 (en) * | 2002-06-17 | 2004-01-29 | Glaxo Group Limited | Purine derivatives as liver x receptor agonists |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7495005B2 (en) * | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
US7569574B2 (en) | 2002-08-22 | 2009-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
DE10254304A1 (de) * | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
US7566707B2 (en) * | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
CA2533715A1 (en) | 2003-07-31 | 2005-02-10 | Schering Corporation | Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction |
AR047948A1 (es) * | 2003-11-21 | 2006-03-15 | Schering Corp | Formulaciuones de inhibidores de la fosfodiesterasa v |
DE10355304A1 (de) | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
US7501426B2 (en) * | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004009039A1 (de) * | 2004-02-23 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel |
US7393847B2 (en) | 2004-03-13 | 2008-07-01 | Boehringer Ingleheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
US7179809B2 (en) * | 2004-04-10 | 2007-02-20 | Boehringer Ingelheim International Gmbh | 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions |
US7439370B2 (en) * | 2004-05-10 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
DE102004030502A1 (de) * | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
DE102004043944A1 (de) * | 2004-09-11 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
DE102004044221A1 (de) * | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
DE102004054054A1 (de) * | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
EA030606B1 (ru) | 2006-05-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Способы приготовления лекарственного средства, содержащего полиморфы |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
EP2057160A1 (en) | 2006-08-08 | 2009-05-13 | Boehringer Ingelheim International GmbH | Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus |
KR101610005B1 (ko) * | 2007-08-17 | 2016-04-08 | 베링거 인겔하임 인터내셔날 게엠베하 | Fab 관련 질환의 치료에 사용하기 위한 푸린 유도체 |
PE20140960A1 (es) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
EA031225B1 (ru) * | 2008-08-15 | 2018-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Ингибиторы дпп-4 для заживления ран |
EP2344195A2 (en) | 2008-09-10 | 2011-07-20 | Boehringer Ingelheim International GmbH | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
BRPI0923121A2 (pt) | 2008-12-23 | 2015-08-11 | Boehringer Ingelheim Int | Formas salinas de compostos orgânico |
TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
ES2760917T3 (es) | 2009-11-27 | 2020-05-18 | Boehringer Ingelheim Int | Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina |
JP6034781B2 (ja) | 2010-05-05 | 2016-11-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 併用療法 |
EA201991014A1 (ru) | 2010-06-24 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение диабета |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
MX366629B (es) | 2011-07-15 | 2019-07-17 | Boehringer Ingelheim Int | Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas. |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
JP2019517542A (ja) | 2016-06-10 | 2019-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | リナグリプチンおよびメトホルミンの組合せ |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6903224B2 (en) * | 1988-04-11 | 2005-06-07 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes |
US5064825A (en) * | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
JPH0372480A (ja) * | 1989-08-10 | 1991-03-27 | Hokuriku Seiyaku Co Ltd | キサンチン誘導体及びそれらを有効成分とする気管支拡張剤 |
CA2030112A1 (en) * | 1989-11-24 | 1991-05-25 | Yasuo Ito | Xanthine compound, method for preparing thereof, and a pharmaceutical composition comprising the same |
IL98559A0 (en) * | 1990-06-21 | 1992-07-15 | Schering Corp | Polycyclic guanine derivatives |
JPH04128285A (ja) * | 1990-06-27 | 1992-04-28 | Hokuriku Seiyaku Co Ltd | キサンチン誘導体 |
JPH04279586A (ja) * | 1991-03-05 | 1992-10-05 | Hokuriku Seiyaku Co Ltd | キサンチン誘導体 |
JPH051065A (ja) * | 1991-06-20 | 1993-01-08 | Hokuriku Seiyaku Co Ltd | キサンチン誘導体 |
DE59208572D1 (de) * | 1991-10-17 | 1997-07-10 | Ciba Geigy Ag | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
DE4411660A1 (de) * | 1994-04-05 | 1995-10-12 | Hoechst Ag | Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung |
DE19540798A1 (de) * | 1995-11-02 | 1997-05-07 | Hoechst Ag | Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel |
ATE226583T1 (de) * | 1996-06-07 | 2002-11-15 | Hoechst Ag | Verwendung von theophyllinderivaten zur behandlung und propylaxe von schockzuständen, neue xanthinverbindungen und verfahren zu deren herstellung |
HUP0301622A3 (en) * | 2000-07-04 | 2006-05-29 | Novo Nordisk As | Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them |
US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
NZ528216A (en) * | 2001-02-24 | 2006-12-22 | Boehringer Ingelheim Pharma | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US6869947B2 (en) * | 2001-07-03 | 2005-03-22 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
EP1421084B1 (en) | 2001-08-28 | 2008-05-14 | Schering Corporation | Polycyclic guanine phosphodiesterase v inhibitors |
EP1463727A2 (en) * | 2001-09-19 | 2004-10-06 | Novo Nordisk A/S | Heterocyclic compounds that are inhibitors of the enzyme dpp-iv |
EP1442042A1 (en) | 2001-11-09 | 2004-08-04 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
ATE409466T1 (de) * | 2002-01-11 | 2008-10-15 | Novo Nordisk As | Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen |
JP2004043429A (ja) * | 2002-02-25 | 2004-02-12 | Eisai Co Ltd | 新規キサンチン誘導体およびdppiv阻害剤 |
TW200404802A (en) * | 2002-05-31 | 2004-04-01 | Schering Corp | Xanthine phosphodiesterase V inhibitor polymorphs |
WO2004009091A1 (en) * | 2002-06-17 | 2004-01-29 | Glaxo Group Limited | Purine derivatives as liver x receptor agonists |
KR101150449B1 (ko) * | 2002-08-21 | 2012-06-01 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 8-[3-아미노-피페리딘-1-일]-크산틴, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
AU2003269850A1 (en) * | 2002-10-08 | 2004-05-04 | Novo Nordisk A/S | Hemisuccinate salts of heterocyclic dpp-iv inhibitors |
AU2003280680A1 (en) * | 2002-11-01 | 2004-06-18 | Sumitomo Pharmaceuticals Co., Ltd. | Xanthine compound |
US7247639B2 (en) * | 2003-06-06 | 2007-07-24 | Endacea, Inc. | A1 adenosine receptor antagonists |
CA2533715A1 (en) * | 2003-07-31 | 2005-02-10 | Schering Corporation | Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction |
DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
-
2003
- 2003-05-30 CA CA002483923A patent/CA2483923A1/en not_active Abandoned
- 2003-05-30 MX MXPA04011862A patent/MXPA04011862A/es active IP Right Grant
- 2003-05-30 WO PCT/US2003/017042 patent/WO2003101992A1/en active IP Right Grant
- 2003-05-30 CN CNB038124971A patent/CN100497336C/zh not_active Expired - Fee Related
- 2003-05-30 DE DE60307628T patent/DE60307628T2/de not_active Expired - Lifetime
- 2003-05-30 AR ARP030101921A patent/AR040232A1/es unknown
- 2003-05-30 PT PT03734281T patent/PT1509525E/pt unknown
- 2003-05-30 AU AU2003238822A patent/AU2003238822A1/en not_active Abandoned
- 2003-05-30 EP EP03734281A patent/EP1509525B9/en not_active Expired - Lifetime
- 2003-05-30 AT AT03734281T patent/ATE336494T1/de not_active IP Right Cessation
- 2003-05-30 DK DK03734281T patent/DK1509525T5/da active
- 2003-05-30 ES ES03734281T patent/ES2270047T3/es not_active Expired - Lifetime
- 2003-05-30 CN CNA2009101321189A patent/CN101538224A/zh active Pending
- 2003-05-30 US US10/449,526 patent/US7074923B2/en not_active Expired - Fee Related
- 2003-05-30 JP JP2004509683A patent/JP2005529934A/ja active Pending
-
2004
- 2004-10-27 ZA ZA200408719A patent/ZA200408719B/en unknown
-
2005
- 2005-03-03 HK HK05101860A patent/HK1068139A1/xx not_active IP Right Cessation
-
2006
- 2006-05-08 US US11/429,719 patent/US7786301B2/en not_active Expired - Fee Related
- 2006-11-13 CY CY20061101635T patent/CY1105774T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
US7074923B2 (en) | 2006-07-11 |
CN100497336C (zh) | 2009-06-10 |
CN1668618A (zh) | 2005-09-14 |
DE60307628D1 (de) | 2006-09-28 |
US20030232987A1 (en) | 2003-12-18 |
CN101538224A (zh) | 2009-09-23 |
WO2003101992A1 (en) | 2003-12-11 |
EP1509525B1 (en) | 2006-08-16 |
DK1509525T5 (da) | 2007-07-30 |
AR040232A1 (es) | 2005-03-23 |
EP1509525B9 (en) | 2007-10-31 |
PT1509525E (pt) | 2006-12-29 |
HK1068139A1 (en) | 2005-04-22 |
JP2005529934A (ja) | 2005-10-06 |
MXPA04011862A (es) | 2005-03-31 |
ZA200408719B (en) | 2005-11-15 |
CY1105774T1 (el) | 2011-02-02 |
CA2483923A1 (en) | 2003-12-11 |
EP1509525A1 (en) | 2005-03-02 |
DK1509525T3 (da) | 2006-12-11 |
DE60307628T2 (de) | 2007-08-09 |
US20060205943A1 (en) | 2006-09-14 |
ATE336494T1 (de) | 2006-09-15 |
US7786301B2 (en) | 2010-08-31 |
AU2003238822A1 (en) | 2003-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2270047T3 (es) | Proceso para preparar inhibidores de la fosfodiesterasa v de xantina y sus precursores. | |
ES2544289T3 (es) | Derivados de quinolina y quinoxalina como inhibidores de cinasa | |
ES2326974T3 (es) | Proceso para preparar sales de 5-((r)-2-(5,6-dietil-indan-2-ilamino)-1-hidroxi-etil)-8-hidroxi-(1h)-quinolin-2-ona, utiles como agonistas adrenoceptores. | |
ES2374379T3 (es) | Síntesis exo y diastereoselectiva de análogos de himbacina. | |
CA2154721C (en) | 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative | |
ES2929327T3 (es) | Proceso para la preparación de Indacaterol e intermedios del mismos | |
US20020042424A1 (en) | 2- (2-amino-1, 6-dihydro-6 -oxo-purin-9 -yl) methoxy-1, 3 -propanediol derivative | |
ES2360721T3 (es) | Síntesis de análogos de himbacina. | |
LT3869B (en) | Tertiary hydroxyalkylxantines, process for the preparation thereof and pharmaceutical composition containing them | |
CS1092A3 (en) | Azole derivatives, process of their preparation and their use | |
HU198493B (en) | Process for producing new pyrazolo/3,4-d/pyrimidine derivatives and pharmaceutical compositions comprising same | |
US5543414A (en) | Achiral amino acid acyl esters of ganciclovir and its derivatives | |
US20100311741A1 (en) | Bicyclosulfonyl Acid (BCSA) Compounds and Their Use as Therapeutic Agents | |
US6215017B1 (en) | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative | |
HU180240B (en) | Process for producing new,substituted 1,3-diaryl-2-iminoimidasolidines and 2-imino-hexahydro-pyrimidines | |
US4027025A (en) | 8-Azapurine derivatives | |
ES2364350T3 (es) | Procedimiento para la preparación de ácido 1-metilindazol-3-carboxílico. | |
ES2180923T5 (es) | Proceso para la preparacion de derivados de purina. | |
JPH072749B2 (ja) | スピロ[4.5デカン誘導体およびその製造方法 | |
EP1175420B1 (en) | Process for preparing n6-substituted deaza-adenosine derivatives | |
EP1719772A1 (en) | Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof | |
KR101372788B1 (ko) | 고순도의 페메트렉시드 이나트륨 염의 제조방법 | |
PT88244B (pt) | Processo para a preparacao de derivados de tetrazole antagonistas de leucotrienos | |
JP2011520886A (ja) | ジヒドロチエノ[3,2−d]ピリミジンジオール類及び類似のピリミジンジオール類の合成 | |
JPH033668B2 (US07786301-20100831-C00010.png) |